McDermott Advises Biotechnology Innovators DiogenX on its First Round of Financing to Develop Diabetes Breakthrough treatments


McDermott Will & Emery advised DiogenX on its first round of financing from a consortium of investors comprising Advent France Biotechnology (AFB), Boehringer Ingelheim Venture Fund and the US fund JDRF T1D, totaling €4.5 million.

DiogenX is a pre-clinical biotechnology company specializing in the development of pancreatic beta cell modulators for the treatment of Type 1 diabetes (T1D). Based upon the discoveries of Dr. Patrick Collombat’s laboratory (Inserm, CNRS, University of Nice), DiogenX is developing an innovative therapy that could become the first beta cell regeneration drug for diabetes. Therapies that directly modify the biology of beta cells can stop and even reverse the loss of function that occurs in T1D.

McDermott’s team was led by Anthony Paronneau and included Fanny Rech, who advised on the corporate aspects of the transaction, both in Paris.

JDRF T1D was advised by Orsay Avocats Associés.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.